TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03366350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematological stem cell transplantation
Description: Patients receive allogeneic hematological stem cell transplantation after they achieve MRD- CR through CAR-T therapy.
Study: NCT03848546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PDA
Description: Subjects receive personal dietary fiber advice to increase their fiber intake. This advice will be provided using an online web-portal, where subjects can choose high-fiber alternatives that closely match their own intake. The aim is to swap product for low in fiber for a high fiber alternative (such as white bread, whole wheat bread).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (no intervention)
Description: No intervention
Study: NCT00835861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Women randomized to the Insulin group will receive standard diet and glycemic monitoring education. They will be initiated on weight based Regular and NPH insulin at a total dosage of 0.7units/kg in the first trimester or 0.8units/kg in the second trimester divided as 2/3 of the total dosage (with 2/3 given as NPH and 1/3 given as Regular) administered before breakfast and 1/3 of the total dosage (with 1/2 given as NPH and 1/2 given as Regular)administered with dinner. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to achieve optimal glycemic control with fasting values \<90 and one hour post prandial values \<130.
Study: NCT03521622

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: brief counseling
Description: Brief counseling for motivated smoker 5 As model Brief counseling for not motivated smokers 5 Rs model Brief counseling for motivated risky drinkers simple advice Brief counseling for not motivated risky drinkers brief alcohol intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief counseling
Description: Brief counseling for motivated smoker 5 As model Brief counseling for not motivated smokers 5 Rs model Brief counseling for motivated risky drinkers simple advice Brief counseling for not motivated risky drinkers brief alcohol intervention
Study: NCT03705221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Parent Carers group programme
Description: Peer-led group-based weekly programme.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Parent Carers online resources
Description: Online resources related to health and wellbeing
Study: NCT03723460

Intervention type: OTHER
Intervention: Passive Dietary Monitoring
Description: Passive dietary monitoring devices will be used to monitor dietary intake in household in communities in Ghana and Kenya
Study: NCT03654495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergame training
Description: Training on Medical Device (MD): Dividat Senso, DIV-SENSO-H, Dividat GmbH, Software development: ISO 62304:2016; designed to train aspects of executive functions (EFs; divided attention, working memory, inhibition, and shifting) and physical functions through Virtual Reality video game training.~FITT training principles are implemented; Frequency: three times per week, Intensity: individually adapted VG (allowing training progression), Type: combination of cognitive and motor training, and Time: 20 min training sessions. Training lasts 6 weeks (18 training sessions). Participants train 20 min, three times per week. Training includes one session of each VG (4 min) in a pre-defined order and short breaks (\~1 min) for game change.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care Training
Description: Routine (standard) therapy given based on conventional current-best-evidence Rehabilitation. Preoperative Phase: Diminish inflammation, swelling, and pain; Restore normal range of motion (especially knee extension); Restore voluntary muscle activation Immediate Postoperative Phase (Day 1-7): Restore full passive knee extension; Diminish joint swelling and pain; Restore independent ambulation Early Rehabilitation Phase (Week 2-4): Maintain full passive knee extension; Gradually increase knee flexion; Muscle training Controlled Ambulation Phase (Week 4-10): Restore full knee ROM; Improve lower extremity strength; Enhance proprioception, balance, and neuromuscular control Advanced Activity Phase (Week 10-16): Normalize lower extremity strength; Enhance muscular power and endurance; Improve neuromuscular control; Perform selected sport-specific drills.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Training
Description: Routine (standard) therapy given based on conventional current-best-evidence Rehabilitation. Preoperative Phase: Diminish inflammation, swelling, and pain; Restore normal range of motion (especially knee extension); Restore voluntary muscle activation Immediate Postoperative Phase (Day 1-7): Restore full passive knee extension; Diminish joint swelling and pain; Restore independent ambulation Early Rehabilitation Phase (Week 2-4): Maintain full passive knee extension; Gradually increase knee flexion; Muscle training Controlled Ambulation Phase (Week 4-10): Restore full knee ROM; Improve lower extremity strength; Enhance proprioception, balance, and neuromuscular control Advanced Activity Phase (Week 10-16): Normalize lower extremity strength; Enhance muscular power and endurance; Improve neuromuscular control; Perform selected sport-specific drills.
Study: NCT05072431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SVVR training program
Description: The SVVR training program is consisted of five scenarios with tasks. Before the SVVR training implementation, the research team provided 10-minute orientation session to introduce the purpose of the training. The 3D VR professional taught the participants how to wear the 3D VR helmets and select the VR scenes, so that the participants could practice multiple times.
Study: NCT04507282

Intervention type: DRUG
Intervention: LMWH
Description: COVID 19 positive patients anticogulation level, subprophylactic level and prophylactic level
Study: NCT00753402

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Endotoxin, Lipopolysaccharide, LPS
Description: Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (\~5 minutes)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Endotoxin, Lipopolysaccharide, LPS
Description: Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (\~5 minutes)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Endotoxin, Epinephrine
Description: Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (\~5 minutes/Epinephrine 30mcg/kg/min
Study: NCT01149174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin-C 40 mg
Description: Intravesical instillation of Mitomycin-C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin-C 40 mg
Description: Intravesical instillation of Mitomycin-C
Study: NCT01662076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homeopathic Remedies
Description: The homeopathic remedy will be administered as either 1 globule sublingual or 0.2 mL oral (depending on chosen formulation) up to 3 times per day. The homeopath will decide which formulation will be used. Homeopathic remedies prepared according to the standards as set out by Health Canada. The caregiver or patient will be asked to administer the homeopathic remedy at least 30 minutes before or after taking other medications, food and strong smelling substances (such as camphor, mint, or coffee).
Study: NCT02784028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SGM-101
Description: Administration of SGM-101 prior surgery
Study: NCT03615742

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Inhalation of air through a Turbuhaler that contains no medication, as a control.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation of air through a Turbuhaler that contains no medication, as a control.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 1.6mg of budesonide from a Turbuhaler.
Study: NCT04631354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: S-770108 Inhaler A1
Description: Dry powder inhaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: S-770108 Inhaler A1
Description: Dry powder inhaler
Study: NCT02007525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Description: Participants will attend one weekly 60 minute hatha yoga class taught by a certified yoga instructor for 6 weeks. Each participant is to practice yoga at home 3-5 days per week. Paper logs will be provided to record date, time and duration of yoga practice each week.
Study: NCT03433573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abbott Sensor Based Glucose Monitoring System
Description: Subjects will wear the Abbott Sensor Based Glucose Monitoring System and will be asked to perform 4 blood glucose tests per day (pre-meal and before bedtime). Subjects will be asked to scan the sensor when each blood glucose test is performed.
Study: NCT03615742

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: 1.6mg of budesonide from a Turbuhaler.
Study: NCT02070250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: From Cancer to Health (C2H-D)
Description: From Cancer to Health gives people with cancer the information and tools they need to manage their stress to improve their health throughout the cancer journey. Each institution involved in this study will implement the core techniques of the C2H-D Intervention but may alter the format somewhat to meet their patient population needs (e.g., shorten hourly 18 week intervention into 2-hour 9 week intervention).
Study: NCT05760859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Initial cue
Description: Symptom volunteered by the patient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Initial cue
Description: Symptom volunteered by the patient
Study: NCT03615742

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Filtered Air
Description: Exposure to HEPA filtered air, as a control.
Study: NCT03615742

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Filtered Air
Description: Exposure to HEPA filtered air, as a control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diesel Exhaust
Description: Diesel exhaust standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
Study: NCT03343626

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (normal saline (0.9% NaCl) IM injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (normal saline (0.9% NaCl) IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIZV
Description: Purified inactivated Zika virus vaccine with aluminum hydroxide adjuvant IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIZV
Description: Purified inactivated Zika virus vaccine with aluminum hydroxide adjuvant IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIZV
Description: Purified inactivated Zika virus vaccine with aluminum hydroxide adjuvant IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIZV
Description: Purified inactivated Zika virus vaccine with aluminum hydroxide adjuvant IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIZV
Description: Purified inactivated Zika virus vaccine with aluminum hydroxide adjuvant IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIZV
Description: Purified inactivated Zika virus vaccine with aluminum hydroxide adjuvant IM injection.
Study: NCT04022863

Intervention type: DIAGNOSTIC_TEST
Intervention: TEP
Description: Tumor Educated Platelets
Study: NCT03615742

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diesel Exhaust
Description: Diesel exhaust standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
Study: NCT04022863

Intervention type: DIAGNOSTIC_TEST
Intervention: TEP
Description: Tumor Educated Platelets

Intervention type: DIAGNOSTIC_TEST
Intervention: TEP
Description: Tumor Educated Platelets

Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA
Description: circulating tumor DNA

Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA
Description: circulating tumor DNA

Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA
Description: circulating tumor DNA
Study: NCT03068702

Intervention type: DEVICE
Intervention: Optical Coherence Tomography Angiography
Study: NCT00602420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naproxen
Description: Oral naproxen twice daily for 5-8 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral placebo twice daily for 5-8 days.
Study: NCT03919357

Intervention type: BEHAVIORAL
Intervention: BMT-i
Description: Passing the BMT-i test

Intervention type: BEHAVIORAL
Intervention: BMT-i
Description: Passing the BMT-i test

Intervention type: BEHAVIORAL
Intervention: BMT-i
Description: Passing the BMT-i test

Intervention type: BEHAVIORAL
Intervention: BMT-i
Description: Passing the BMT-i test
Study: NCT00234923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lopinavir/ritonavir
Description: 400 mg lopinavir/ 100 mg ritonavir, BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lopinavir/ritonavir
Description: 400 mg lopinavir/ 100 mg ritonavir, BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamivudine/zidovudine
Description: 300mg lamivudine/150mg zidovudine, BID
Study: NCT06359613

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutrient rich food product
Description: Cupcakes from flour blends of Sorghum, chickpea, Flaxseed and Almond will be prepared and flour concentration will be so adjusted to provide \>20% daily value of nutrients for children of 3-8 years of age. 2 cupcakes/ day, 35g each will be provided to participants for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: food product
Description: Cupcakes from usually used gluten free rice flour will be prepared. 2 cupcakes/ day, 35g each will be provided to participants for 12 weeks.
Study: NCT03953833

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003.
Description: Usage: Intravenous infusion; Dose escalation stage: doses 0.6, 1.2, 2.4, 3.6, 4.8 mg / kg, 1-6subjects each. Dose expansion stage: 20 subjects are enrolled and take the recommended dose based on the result of dose escalation stage.~Infusion time：90 minutes(90min-106min suggested) for the first time; if no infusion reaction happens, the follow-up time is adjusted to at least30 minutes(30min-40min suggested).Dose escalation stage: treatment cycle is administered every 21days,the infusion is taken at the first day of each treatment cycle.Observation period of DLT is the 21st day of the first treatment cycle.
Study: NCT03545074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Awareness Practices- English
Description: The 6-week intervention aimed at teaching mindfulness-based strategies to participants (in English)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Awareness Practices- Spanish
Description: The 6-week intervention aimed at teaching mindfulness-based strategies to participants (in Spanish)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education - English
Description: The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general (in English)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education - Spanish
Description: The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general (in Spanish)
Study: NCT06206993

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training including the Kieser A5 pelvic floor trainer
Description: In the RECON Study participants of both arms will receive machine-based resistance training. Experimental group will additionally train with Kieser A5 pelvic floor trainer.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training without pelvic floor biofeedback Kieser A5 pelvic floor trainer
Description: In the RECON Study participants of both arms will receive machine-based resistance training. Active Comparator trains without the pelvic floor biofeedback device A5 and undergo conventional pelvic floor muscle training with a physiotherapist once a week before the resistance training unit starts.
Study: NCT03166241

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: serum interleukin 21
Description: it is cytokine used as a marker to detect it's level in patients with adverse drug reactions

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: serum interleukin 21
Description: it is cytokine used as a marker to detect it's level in patients with adverse drug reactions

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Complete Blood Picture
Description: It is a blood sample will taken from patients to detect any abnormalities in blood component at the start of the study

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liver function test
Description: It is a blood sample will taken from patients to detect any associated liver disease at the start of the study

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Random Blood Sugar
Description: measure blood sugar in patients included in the study at the start of the study

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Erythrocyte Sedimentation Rate
Description: blood sample will be taken from patients to detect any abnormalities in erythrocyte sedimentation rate at the start of the study

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Kidney function tests
Description: blood sample will be taken from patients to detect any kidney disease before the start of the study
Study: NCT01233063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity and Diet Intervention via Alive2
Description: Weekly email/web goal-setting intervention to improve physical activity and diet, with and without additional phone and mail support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity and Diet Intervention via Alive2
Description: Weekly email/web goal-setting intervention to improve physical activity and diet, with and without additional phone and mail support.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physical Activity and Diet Intervention via Alive2
Description: Weekly email/web goal-setting intervention to improve physical activity and diet, with and without additional phone and mail support.
Study: NCT04519463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylocaine Mucosal Product
Description: Xylocaine 10% Nasal Spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride 0.9%
Study: NCT01748838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX-4430
Description: Ascending single oral doses of CTX-4430 will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross-over, fed a high fat diet and administered different single oral doses of CTX-4430

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: excipient blended with CTX-4430 in capsules

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mannitol
Description: excipient blended with CTX-4430 in capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral doses of placebo will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross over, fed a high fat diet and administered single oral doses of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX-4430
Description: Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Repeat doses of placebo will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: excipient blended with CTX-4430

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mannitol
Description: excipient blended with CTX-4430
Study: NCT01417832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resin infiltration / adhesive
Description: Treatment at baseline of one caries lesion with a resin infiltration conducted under rubber-dam isolation with the Icon-DMG pre-product; treatment at baseline of another caries lesion with an adhesive under rubber-dam isolation with the Prime Bont NT - Dentsply.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with an infiltrant resin, one will be treated with an adhesive resin.
Study: NCT03815162

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Flavanol Cocoa extract
Description: Experimental group

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alkalised cocoa
Description: Control group
Study: NCT01403090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angel Catheter
Description: The Angel Catheter will be inserted in the femoral vein following standard central line placement techniques. Once the catheter is on the Inferior Vena Cava, the filter will be deployed following the manufacturer instructions and secured to the skin.
Study: NCT01849705

Intervention type: OTHER
Intervention: No intervention
Study: NCT03131063

Intervention type: OTHER
Intervention: Antibiotic plasma dosage
Description: Measurement of the concentration of antibiotics administered as part of the routine care of intensive care patients
Study: NCT04361669

Intervention type: OTHER
Intervention: Medication safety review
Description: Implementation of a medication safety review using a clinical decision support system

Intervention type: OTHER
Intervention: Medication safety review
Description: Implementation of a medication safety review using a clinical decision support system